Fact: Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in Dallas, Texas, focused on developing therapies for autoimmune and inflammatory conditions. Its lead candidate is FB-102, a proprietary anti-CD122 monoclonal antibody with potential applications in celiac disease, vitiligo, alopecia areata, and type 1 diabetes. The company has approximately 22 full-time employees and trades on the Nasdaq Capital Market under ticker FBRX.
Interpretation: The company's pipeline shift toward monoclonal antibodies like FB-102 positions it in the high-risk, high-reward autoimmune therapeutics space, where early clinical success can drive significant valuation changes.
Fact: The company was founded on May 3, 2017, by Paul A. Wagner. It has evolved from earlier dermatology-focused efforts (including FB-401, a live biotherapeutic for atopic dermatitis) to its current emphasis on FB-102 for broader autoimmune indications. Some sources note a possible prior association with Tocagen Inc. via restructuring or merger.
Uncertainty: Exact details of any predecessor entity (e.g., Tocagen) or precise timeline of pipeline pivot are not fully detailed in public summaries and may require review of SEC filings for confirmation.
Interpretation: The recent positive data readouts have catalyzed investor interest, highlighting the potential of FB-102 in dermatological autoimmune conditions like vitiligo.
| Metric | Value/Details |
|---|---|
| 52-Week Range | $9.10 – $35.80+ (recent highs exceeded during surge) |
| Recent Price (post-surge, ~July 9-10, 2026) | ~$20–$36 (volatile; intraday swings of 50%+ reported) |
| YTD Return | ~17–35% (pre/post-surge data varies) |
| 1-Year Return | ~155–194% |
| 5-Year Return | ~-96% (long-term decline from historical peaks) |
| All-Time High | ~$6,525+ (May 2017; adjusted for splits/restructuring) |
| Volume (recent avg) | ~590K–645K shares |
Data Limitation: Stock prices are highly volatile for clinical-stage biotechs and reflect real-time market reactions. Historical data may be adjusted for corporate actions; always verify with live sources. Performance figures are approximate aggregates from multiple reports as of July 9-10, 2026.
| Category | Details |
|---|---|
| Facts | Pipeline focus, employee count, headquarters, recent trial results, founding date (all directly from company disclosures and news wires). |
| Interpretations | Pipeline pivot significance, potential market impact of positive data, valuation sensitivity to clinical milestones. |
| Uncertainties | Long-term efficacy/safety of FB-102, future trial outcomes, exact corporate history details, precise current market cap amid volatility. |
Overall Limitations/Assumptions: Information compiled from publicly available web sources as of July 10, 2026. Biotech stocks carry high risk of failure in clinical development; this is not investment advice. Verify all data with primary sources (SEC filings, company press releases) as prices and news evolve rapidly. No financial advice implied.